KPV
Research OnlyLys-Pro-Val is the C-terminal tripeptide motif of alpha-MSH. KPV reduced inflammatory readouts in cell and mouse colitis models, including a PepT1 uptake study. Human drug exposure, pharmacokinetics, safety and clinical benefit remain unestablished.
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) · C-terminal alpha-MSH tripeptide
The cited KPV evidence is preclinical and does not establish clinical benefit.
- Preclinical
- 43%
- Human research
- 0%
Based on 7 cited sources
Seven visible records: six publications and one FDA record. Three papers provide direct preclinical KPV evidence; parent alpha-MSH studies and reviews are contextual. No direct human administration study is counted.
KPV is the Lys-Pro-Val tripeptide at the C-terminus of alpha-melanocyte-stimulating hormone. This structural relationship does not make the parent hormone’s results evidence for administered KPV.
Direct experimental evidence
Dalmasso and colleagues tested KPV in human-derived intestinal and immune cell lines and in two mouse colitis models. Their experiments associated PepT1-mediated cellular uptake with reduced NF-kappaB/MAPK signaling and inflammatory readouts; oral KPV reduced colitis measures in mice. This is cell and animal evidence, not a human pharmacokinetic or efficacy study. A separate later study reported reduced colonic PEPT1 expression during inflammation in studied samples and mice, so the transport story should not be generalized beyond the experimental setting. PMID:18061177 · PMID:24583477
Other preclinical work examined receptor-independent anti-inflammatory effects. It does not establish that KPV treats inflammatory bowel disease, skin disease or any other condition in people, nor does it prove the absence of pigmentation effects in humans. Studies of KdPT, a modified tripeptide, should also remain distinct from KPV. PMID:12750433 · KdPT study, PMID:21741932
Human evidence and safety boundary
No controlled KPV treatment trial or human drug-exposure dataset was identified. FDA states that it has identified no human exposure data for KPV drug products by any route and lacks information needed to determine whether administration would cause harm. Interactions and combination effects with other peptides are unknown. FDA compounding safety review
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare KPV
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
LL37 · Human cathelicidin antimicrobial peptide LL-37
LL-37 is the active human cathelicidin peptide. Three topical wound trials studied native LL-37, with mixed outcomes; an oral trial used engineered bacteria expressing LL-37. These results do not establish systemic benefit.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymalin
Thymulin · Thymic Factor · Timalin +1
A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.
Compared With
3 comparisonsConditions Studied
4 entries- KPV for Inflammatory Bowel Disease KPV has been studied extensively in preclinical models of inflammatory bowel disease (IBD). The tripeptide inhibits NF-kB activati…
- KPV for Gut Inflammation KPV reduced inflammatory markers in experimental intestinal models. The C-terminal motif occurs in alpha-MSH, but this does not es…
- KPV for Skin Inflammation The cited review concerns alpha-MSH and related melanocortin peptides; it does not provide a direct KPV clinical dermatitis study.…
- KPV for Anti-Inflammatory KPV reduced inflammatory readouts in cell and animal experiments; one study found effects that did not require melanocortin-recept…